Novel Microtubule Polymerization Inhibitor with Potent Antiproliferative and Antitumor Activity
- 1 March 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (5), 1910-1915
- https://doi.org/10.1158/0008-5472.can-08-0877
Abstract
Microtubule-stabilizing and microtubule-destabilizing agents are commonly used as anticancer agents. Although highly effective, success with these agents has been limited due to their relative insolubility, cumbersome synthesis/purification, toxic side effects, and development of multidrug resistance. Hence, the identification of improved agents that circumvent one or more of these problems is warranted. We recently described the rational design of a series of triazole-based compounds as antimitotic agents. Members of this N-substituted 1,2,4-triazole family of compounds exhibit potent tubulin polymerization inhibition and broad spectrum cellular cytotoxicity. Here, we extensively characterize the in vitro and in vivo effects of our lead compound from the series 1-methyl-5-(3-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazole-4-yl)-1H-indole, designated T115. We show that T115 competes with colchicine for its binding pocket in tubulin, produces robust inhibition of tubulin polymerization, and disrupts the microtubule network system inside the cells. In addition, T115 arrests human cancer cells in the G2-M phase of cell cycling, a hallmark of microtubule destabilizing drugs. T115 also inhibits cell viability of several cancer cell lines, including multidrug-resistant cell lines, in the low nanomolar range. No cytotoxicity was observed by T115 against normal human skin fibroblasts cell lines, and acute toxicity studies in normal nontumor-bearing mice indicated that T115 is well-tolerated in vivo (maximum total tolerated dose, 400 mg/kg). In a mouse xenograft model using human colorectal (HT-29) and prostate (PC3) cancer cells, T115 significantly inhibited tumor growth when administered i.p. Taken together, our results suggest that T115 is a potential drug candidate for cancer chemotherapy. [Cancer Res 2009;69(5):1910–5]Keywords
This publication has 24 references indexed in Scilit:
- Highly Potent Triazole-Based Tubulin Polymerization InhibitorsJournal of Medicinal Chemistry, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-Inducing Activity in HL60 and in MDR Cell LinesJournal of Medicinal Chemistry, 2005
- The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell DeathThe American Journal of Pathology, 2004
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Refined structure of αβ-tubulin at 3.5 Å resolution 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2001
- Chemotherapeutic neuropathyCurrent Opinion in Neurology, 1999
- Antineoplastic Agents. 410. Asymmetric Hydroxylation of trans-Combretastatin A-4Journal of Medicinal Chemistry, 1999
- A Preliminary Risk-Benefit Assessment of PaclitaxelDrug Safety, 1995
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989